Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Colorectal Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasms 6Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Glioblastoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Diseases 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Advanced Solid Tumors 2Advanced Solid Tumor 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

Gemcitabine 20Cisplatin 17pembrolizumab 11Magnetic Resonance Spectroscopy 7durvalumab 5Platinum 5Irinotecan 5Fluorouracil 51,2-diaminocyclohexaneplatinum II citrate 5Leucovorin 4Taxes 3Oxaliplatin 3Nivolumab 3Fluorodeoxyglucose F18 3Carboplatin 3Biopsy 3Bevacizumab 3spartalizumab 2pemigatinib 2ivosidenib 2fludarabine 2budigalimab 2atezolizumab 2Specimen Handling 2Radiosurgery 2Paclitaxel 2Immunoglobulin G 2Floxuridine 2FAPI-46 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Cholangiocarcinoma × spartalizumab × Clear all
NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Symphogen A/S

Phase 1 Completed
48 enrolled
GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04641871 2024-06-26

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Symphogen A/S

Phase 1 Completed
78 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡